Evaluation of the Protection Provided by Hepatitis B Vaccination in India

Indian J Pediatr. 2018 Jul;85(7):510-516. doi: 10.1007/s12098-017-2601-0. Epub 2018 Jan 10.

Abstract

Objective: In India, Hepatitis B vaccination is recommended at 6 wk except for hospital-deliveries. The authors examined protection afforded by the birth dose.

Methods: A case-control study was done. HBsAg and HBcAb were tested in 2671 children, 1 to 5 y and HBsAb was evaluated in a subset of 1413 children. Vaccination history was recorded. Cases were HBsAg carriers. In another analysis, children who got infected (HBsAg and/or HBcAb positive) were considered as cases. Exposed were the unvaccinated. In another analysis, exposed were those vaccinated without the birth dose.

Results: The odds ratio (OR) for HBsAg positivity with birth vaccination was 0.35 (95% CI 0.19-0.66); while with vaccination at 6 wk was 0.29 (95%CI 0.14-0.61), both compared to unvaccinated. Birth vaccination has no added protection when compared to the unvaccinated. Unvaccinated children in index study had HBsAg positivity of 4.38%. The number needed to treat (NNT) to prevent one case of HBsAg positivity was 32.6 (95% CI, 20.9 to 73.6). The odds of getting HBV infection was 0.42 (CI 0.25-0.68) with birth dose and 0.49 (CI 0.30-0.82) without the birth dose compared to the unvaccinated. Protective antibody (HBsAb) was present in about 70% of the vaccinated. In the unimmunised, in the first 2 y HBsAb protection was present in 40%. The odds ratio (OR) for HBsAb in the fully vaccinated between 4 and 5 y was 1.4 (95%CI 0.9-2.18) compared to the unvaccinated.

Conclusions: The present study lends support to the pragmatic approach of the Government to vaccinate babies born at home starting at 6 wk.

Keywords: Antibody to hepatitis B core antigen; Antibody to hepatitis B surface antigen; Hepatitis B core antigen; Hepatitis B surface antigen; Immunization; Passive immunity.

MeSH terms

  • Case-Control Studies
  • Child, Preschool
  • Female
  • Hepatitis B / prevention & control*
  • Hepatitis B Surface Antigens / analysis
  • Hepatitis B Vaccines / therapeutic use*
  • Hepatitis B virus
  • Humans
  • India
  • Infant
  • Male
  • Vaccination

Substances

  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines